FIELD: medicine, pharmaceutics.
SUBSTANCE: presented group of inventions refers to biotechnology, and concerns a DLK1-Fc fused protein and using it for the metastases inhibition, a polynucleotide coding such a protein, an expression vector containing the polynucleotide, a host cell producing the above fused protein, a method for producing the fused protein by culturing the above host cell, a composition containing the above fused protein, and a method for the metastases inhibition. The characterised fused protein contains a DLK1 extracellular soluble domain consisting of the amino acid sequence SEQ ID NO:4 and Fc domain of a human antibody.
EFFECT: group of inventions can be used for preparing a therapeutic agent for reduction of cancer cell migration and the metastases inhibition.
11 cl, 36 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGF-R-Fc FUSED PROTEIN AND USE THEREOF | 2012 |
|
RU2560573C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| ANTICANCER AGENT CONTAINING LK8 PROTEIN AS ACTIVE INGREDIENT | 2004 |
|
RU2306147C2 |
| INHIBITION OF TUMOUR METASTASES BY ANTIBODIES AGAINST NEUROPILINE-2 | 2007 |
|
RU2437677C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT | 2012 |
|
RU2560589C2 |
| APPLICATION OF FUSED TIMP-GPI CONSTRUCT AND METHOD OF TREATING SKIN INJURES FOR CICATRISATION PREVENTION OR INHIBITION | 2006 |
|
RU2428479C2 |
| ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
| FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
